Juro Sciences Announces Initiation of Phase 1 Clinical Trial of SFG-02 with Transdermal Drug Delivery System Formulation
[Yokohama, Japan, September 10, 2025] – Juro Sciences Inc. (Headquarters: Naka-ku, Yokohama; President & CEO: Hiroshi Nagabukuro) is pleased to announce the completion of the first dosing in its Phase 1 clinical trial of transdermal SFG-02 under development for the treatment of underactive bladder (UAB).
This study is a randomized, single-center, double-blind, placebo-controlled trial conducted in Japan, recruiting healthy adult Japanese and Caucasian participants. It aims to assess the safety, tolerability, and pharmacokinetics of single and repeated transdermal administration of SFG-02.
For more details on the study, please refer to the following link:
https://clinicaltrials.gov/study/NCT07167914
Juro Sciences remains strongly committed to high-quality R&D, regulatory compliance, and strategic partnerships, and continue to strive to deliver innovative pharmacotherapy for UAB, for which there are currently no available medicines.
About Juro Sciences Inc.
Juro Sciences is a biopharmaceutical company dedicated to developing innovative therapies for underactive bladder. Leveraging cutting-edge science and a patient-focused approach, the company is committed to alleviating symptoms and improving the quality of life for patients living with UAB.
About SFG-02
SFG-02 is a novel acetylcholinesterase inhibitor with a newly developed transdermal delivery system formulation in development for the treatment of UAB. In multiple preclinical studies, it demonstrated high selectivity for its molecular target and optimal efficacy in animal models of UAB. The non-clinical data to date show a favorable pharmacokinetic profile designed to maximize efficacy while minimizing side effects. A patent application for this novel transdermal drug delivery system formulation has already been filed. Following the completion of Phase 1, proof-of-concept studies in UAB patients in Japan and the U.S. will be initiated in 2026.
This program is supported by the Japan Agency for Medical Research and Development (AMED) under Strengthening Program for Pharmaceutical Startup Ecosystem Grant Number 25qfb127011 (Project Title: Development of SFG-02 for underactive bladder).
For media inquiries regarding the Company or SFG-02, please contact: